Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|
SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 131.00 | 121.25 | 1.0804 | 1.4355 | |
SK-BR-3 | Linsitinib | 19.9526 | uM | 9 | 156.25 | 92.36 | 92.00 | 121.25 | 0.7588 | -0.0100 |
SK-BR-3 | Linsitinib | 0.0033113 | uM | 9 | 156.25 | 92.36 | 115.00 | 121.25 | 0.9485 | 0.7478 |
SK-BR-3 | Erlotinib | 10 | uM | 9 | 156.25 | 92.36 | 84.00 | 121.25 | 0.6928 | -0.2148 |
SK-BR-3 | Erlotinib | 3.1623 | uM | 9 | 156.25 | 92.36 | 109.00 | 121.25 | 0.8990 | 0.5248 |
SK-BR-3 | 17-AAG | 0.0031623 | uM | 9 | 156.25 | 92.36 | 70.00 | 121.25 | 0.5773 | -0.5065 |
SK-BR-3 | Erlotinib | 0.01 | uM | 9 | 156.25 | 92.36 | 153.00 | 121.25 | 1.2619 | 2.6168 |
SK-BR-3 | Linsitinib | 0.01 | uM | 9 | 156.25 | 92.36 | 128.00 | 121.25 | 1.0557 | 1.2959 |
SK-BR-3 | 17-AAG | 0.0001 | uM | 9 | 156.25 | 92.36 | 164.00 | 121.25 | 1.3526 | 3.3164 |
SK-BR-3 | 17-AAG | 0.01 | uM | 9 | 156.25 | 92.36 | 89.00 | 121.25 | 0.7340 | -0.0902 |
SK-BR-3 | Linsitinib | 10 | uM | 9 | 156.25 | 92.36 | 111.00 | 121.25 | 0.9155 | 0.5971 |
SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 128.00 | 121.25 | 1.0557 | 1.2959 | |
SK-BR-3 | Lapatinib | 1 | uM | 9 | 156.25 | 92.36 | 94.00 | 121.25 | 0.7753 | 0.0457 |
SK-BR-3 | Lapatinib | 10 | uM | 9 | 156.25 | 92.36 | 69.00 | 121.25 | 0.5691 | -0.5242 |
SK-BR-3 | Lapatinib | 0.0033113 | uM | 9 | 156.25 | 92.36 | 153.00 | 121.25 | 1.2619 | 2.6168 |
SK-BR-3 | Linsitinib | 0.1 | uM | 9 | 156.25 | 92.36 | 113.00 | 121.25 | 0.9320 | 0.6714 |
SK-BR-3 | Lapatinib | 0.031623 | uM | 9 | 156.25 | 92.36 | 101.00 | 121.25 | 0.8330 | 0.2557 |
SK-BR-3 | 17-AAG | 0.031623 | uM | 9 | 156.25 | 92.36 | 89.00 | 121.25 | 0.7340 | -0.0902 |
SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 116.00 | 121.25 | 0.9567 | 0.7868 | |
SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 370.00 | 341.75 | 1.0827 | 1.2175 | |
SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 373.00 | 341.75 | 1.0914 | 1.2409 | |
SK-BR-3 | Erlotinib | 0.0033113 | uM | 9 | 312.50 | 200.50 | 232.00 | 341.75 | 0.6789 | 0.2089 |
SK-BR-3 | 17-AAG | 0.001 | uM | 9 | 312.50 | 200.50 | 290.00 | 341.75 | 0.8486 | 0.6156 |
SK-BR-3 | 17-AAG | 0.000066069 | uM | 9 | 312.50 | 200.50 | 315.00 | 341.75 | 0.9217 | 0.7990 |
SK-BR-3 | Linsitinib | 3.1623 | uM | 9 | 312.50 | 200.50 | 211.00 | 341.75 | 0.6174 | 0.0686 |